Ablynx, a Sanofi company

Quick facts

Phase 2 pipeline

• ALX-0061 · Immunology
  ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.
• ALX-0081 · Hematology
  ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation.
• ATN-103
• ReoPro®

Phase 1 pipeline

• PF-05230905

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ablynx, a Sanofi company portfolio CI brief
• Ablynx, a Sanofi company pipeline updates RSS